OSLO, Norway--(BUSINESS WIRE)--Regulatory News:
DiaGenic (OSE:DIAG):
The Australian family 3 patent application (2005250219) has now been granted. The claims allowed cover the use of some important gene sequences in blood sample for detection of cancer, among others, breast cancer. The patent will be valid until 2023.
